Wai Yuen Tong Medicine Holdings Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Wai Yuen Tong Medicine Holdings zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.2% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11
The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | 1,359 | 36 | 173 | 233 | N/A |
| 6/30/2023 | 1,323 | 8 | 153 | 199 | N/A |
| 3/31/2023 | 1,286 | -21 | 132 | 166 | N/A |
| 12/31/2022 | 1,314 | -98 | 149 | 182 | N/A |
| 9/30/2022 | 1,341 | -176 | 165 | 199 | N/A |
| 6/30/2022 | 1,366 | -143 | 154 | 184 | N/A |
| 3/31/2022 | 1,391 | -109 | 143 | 169 | N/A |
| 12/31/2021 | 1,323 | -122 | 142 | 182 | N/A |
| 9/30/2021 | 1,255 | -135 | 141 | 194 | N/A |
| 6/30/2021 | 1,182 | -255 | 247 | 303 | N/A |
| 3/31/2021 | 1,109 | -376 | 353 | 413 | N/A |
| 12/31/2020 | 979 | -98 | 282 | 321 | N/A |
| 9/30/2020 | 849 | 179 | 211 | 229 | N/A |
| 6/30/2020 | 735 | 309 | 86 | 98 | N/A |
| 3/31/2020 | 621 | 439 | -39 | -33 | N/A |
| 12/31/2019 | 655 | 253 | -65 | -54 | N/A |
| 9/30/2019 | 689 | 66 | -91 | -76 | N/A |
| 6/30/2019 | 720 | 71 | -68 | -51 | N/A |
| 3/31/2019 | 751 | 75 | -44 | -27 | N/A |
| 12/31/2018 | 779 | 20 | -86 | -52 | N/A |
| 9/30/2018 | 807 | -35 | -128 | -77 | N/A |
| 6/30/2018 | 826 | -75 | -134 | -77 | N/A |
| 3/31/2018 | 846 | -116 | -140 | -77 | N/A |
| 12/31/2017 | 808 | -106 | -132 | -61 | N/A |
| 9/30/2017 | 770 | -96 | -123 | -46 | N/A |
| 6/30/2017 | 754 | -94 | N/A | -68 | N/A |
| 3/31/2017 | 738 | -93 | N/A | -90 | N/A |
| 12/31/2016 | 769 | -87 | N/A | -65 | N/A |
| 9/30/2016 | 799 | -81 | N/A | -41 | N/A |
| 6/30/2016 | 812 | -28 | N/A | -78 | N/A |
| 3/31/2016 | 825 | 25 | N/A | -116 | N/A |
| 9/30/2015 | 827 | 177 | N/A | -93 | N/A |
| 6/30/2015 | 829 | 149 | N/A | -18 | N/A |
| 3/31/2015 | 831 | 121 | N/A | 58 | N/A |
| 9/30/2014 | 835 | 120 | N/A | 39 | N/A |
| 6/30/2014 | 850 | 144 | N/A | 27 | N/A |
| 3/31/2014 | 865 | 168 | N/A | 15 | N/A |
| 9/30/2013 | 831 | 175 | N/A | -31 | N/A |
| 6/30/2013 | 808 | 162 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 897 über der Sparquote liegt (2%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 897 schneller wachsen werden als der Markt Hong Kong
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 897 in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 897 schneller wachsen werden als der Markt von Hong Kong.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 897 schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 897 in 3 Jahren voraussichtlich hoch sein wird